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Abstract
Several small molecule drugs that bind to the host CCR5 co-receptor and prevent viral entry have been developed for the treatment of HIV-1
infection. The innate variability found in HIV-1 envelope and the complex viral/cellular interactions during entry makes defining resistance to
these inhibitors challenging. Here we found that mapping determinants in the gp160 gene from a primary isolate RU570-VCVres, selected in
culture for resistance to the CCR5 entry inhibitor vicriviroc, was complicated by inactivity of the cloned envelope gene in pseudovirus assays. We
therefore recombined the envelope from RU570-VCVres into a highly active and susceptible ADA gp160 backbone. The chimeric envelopes
generated robust signals in the pseudovirus assay and a 200 amino acid fragment, encompassing a C2-V5 region of the RU570-VCVres envelope,
was required to confer resistance in both the single-cycle assay and in replicating virus. In contrast, a chimeric envelope that contained only the
V3-loop region from this resistant virus was completely susceptible suggesting that the V3-loop changes acquired are context dependent.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; CCR5 co-receptor; gp160; gp120; Virus entry antagonist; Vicriviroc; ResistanceIntroduction
The current standard of care for HIV-1 infection consists of a
combination of antiviral drugs that inhibit one or both of the
essential viral-encoded enzymes, reverse transcriptase and pro-
tease. This treatment strategy has had a major impact on the
treatment outcomes for HIV-1 infection; in many cases
suppressing HIV-1 viral loads to undetectable levels for many
years (Louie andMarkowitz, 2002). However, treatment failures
develop over time in a majority of patients on long-term therapy
and changes to the antiviral regimen are often necessary to
maintain viral suppression (del Rio, 2006). When HIV-1 de-
velops resistance to a particular drug, cross-resistance to other⁎ Corresponding author. Schering-Plough Research Institute, 2015 Galloping
Hill Road, K-15-E403C, 4945, Kenilworth, NJ 07033, USA. Fax: +1 908 740
3032.
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doi:10.1016/j.virol.2007.12.009approved drugs within the same class of compounds can also
occur. This limits the therapeutic options available for those
patients who have developed multi-drug resistance to HIV-1. In
this regard, two new classes of small molecule antiviral drugs
that target viral entry (Tsibris and Kuritzkes, 2007; Westby and
van der Ryst, 2005) or the HIV-1 integrase enzyme (Dayam
et al., 2007) have recently been developed for HIV treatment.
Maraviroc (UK-427,857) (Dorr et al., 2005; Fatkenheuer
et al., 2005) and vicriviroc (SCH-D, SCH-417690) (Gulick
et al., 2007; Schurmann et al., 2007; Strizki et al., 2005) are
CCR5 co-receptor antagonists that block CCR5-tropic HIV-1
viral entry. Vicriviroc has recently advanced to Phase III human
clinical trials in treatment-experienced patients and maraviroc
was recently approved by the FDA for use in treatment-
experienced patients and is marketed as Selzentry. A more
comprehensive review of CCR5 co-receptor inhibitors is
described in reviews by Westby and van der Ryst (2005) and
Tsibris and Kuritzkes (2007). As these compounds are now
being used to treat HIV-1 infection, a clearer understanding for
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has become significantly more important. Currently only
limited data are available from in vitro resistance studies with
different primary isolates (Kuhmann et al., 2004; Marozsan
et al., 2005; Pugach et al., 2007; Trkola et al., 2002; Westby
et al., 2007).
In previous studies, in vitro generated resistant variants of a
sub-type B HIV-1 primary isolate CC1/85 were generated to the
CCR5 co-receptor antagonists, AD101 (Kuhmann et al., 2004;
Trkola et al., 2002) and vicriviroc (Marozsan et al., 2005;
Pugach et al., 2007) in peripheral blood lymphocytes (PBL);
each adapting to growth in the presence of very high concen-
trations of antagonist. Sequence analysis of envelope clones
from the resistant variants revealed different patterns of adaptive
amino acid changes in the envelope protein as a result of the
selective pressure by these different co-receptor antagonists.
CC1/85 escape variants to AD101 contained four V3-loop
amino acid changes that conferred complete resistance to
AD101 (Kuhmann et al., 2004), whereas the CC1/85 virus
culture resistant to vicriviroc developed multiple amino acid
changes throughout gp160 without any changes in the V3
loop relative to the input isolates (Marozsan et al., 2005). InFig. 1. Vicriviroc susceptibility assays for RU570-PC (-□-) and RU570-VCV (-■-) cu
representing week 22 (A), week 45 (B), week 47 (C), and week 93 (D) are presented. C
a nonlinear regression 4-parameter logistic curve fit analysis (R2 values, RU570-PCaddition to these studies, in vitro generated resistant variants to
maraviroc were generated with the same CC1/85 primary
isolate and a Clade G RU570 primary isolate (Westby et al.,
2007). In this study, two adaptive amino acid changes in V3
loop of the CC1/85 isolate, and a deletion of 3 amino acids
within the V3 loop for the RU570 isolate, were primarily
responsible for high-level resistance to maraviroc (Westby et al.,
2007). These changes were distinct for those reported for
AD101 and interestingly these viruses remained susceptible to
SCH-C and aplaviroc.
In addition to understanding the underlying mechanism
involved in the development of resistance to CCR5 antagonists,
concerns still remain as to whether antiviral therapy targeting
the CCR5 co-receptor will drive the emergence of CXCR4-
tropic viruses during prolonged therapy. These viruses usually
appear in the later stages of HIV-1 disease progression as the
immune system becomes impaired, and are associated with a
rapid acceleration in disease progression (Koot et al., 1999;
Philpott, 2003; Shankarappa et al., 1999). However, most of the
HIV-1 variants that developed resistance to CCR5 co-receptor
antagonists in vitro remained CCR5-tropic, with the exception
of one resistant variant (Kuhmann et al., 2004; Marozsan et al.,ltures passaged in PM-1 cells were performed in PBL and dose–response curves
urves were generated with PrismGraphPad Software program, Version 4.0 using
: 0.90–0.98, RU570-VCV: 0.80–0.97).
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2007). Although clinical data are limited, accelerated viral
evolution toward CXCR4 has not been observed in the on-going
CCR5 co-receptor antagonist clinical trials. In a small number
of patients treated with maraviroc, CXCR4-tropic virus became
detectable over the course of ten days of monotherapy.
However, it was shown that these patients had pre-existing
CXCR4 tropic virus which fell below the detection limits of a
phenotypic assay used to screen patients and did not result from
de novo viral mutations (Westby et al., 2006).Fig. 2. (A) Schematic of the chimeric envelopes generated by homologous recombin
sequences from VCVres gp120 clones and the filled bars represent the envelope sequen
acid changes that were identified in VCVres gp120 are designated by arrows using H
chimeric RU570-PC envelopes were analyzed for vicriviroc susceptibility in U87-CD
pseudovirus (□—RU570-PC gp160, ●—RU570-PC-C2-C3res, ■—RU570-PC-C2
nonlinear regression 4-parameter logistic curve-fit analysis with PrismGraphPad SoIn order to better understand HIV-1 resistance to vicriviroc, a
vicriviroc-resistant virus culture was generated by passaging a
clade G, HIV-1 primary isolate RU570 in PM-1 cells in the
presence of increasing concentrations of vicriviroc. This report
describes the phenotypic and genotypic properties of these viral
cultures using a novel approach to map the genetic determinants
of resistance. We used homologous recombination in bacteria to
transfer gp120 domains from resistant envelope clones into the
background of a heterologous, vicriviroc susceptible envelope
and screened for resistance to vicriviroc with these chimerication in BJ5183 E. coli bacterial cultures. The hatched bars represent the gp120
ce from RU570-PC gp160 into which these sequences were recombined. Amino
XB2 amino acid coordinates. (B) HIV-1 pseudoviruses generated with VCVres
4-CCR5 cells. Dose–response curves for vicriviroc-susceptibility for each HIV-1
-V4res, ○—RU570-PC-C2-V5res) are represented. Data were analyzed using a
ftware Version 4.0 (R2 values, RU570-PC: 0.91, RU570-PC-C2-V5res: 0.95).
Fig. 3. The relative infectivity (RLU/p24) of HIV-1 pseudoviruses generated
with chimeric envelopes was compared to ADA gp160 and RU570-PC gp160
pseudoviruses. Data represent the luciferase activity (RLU) in cells 72 h post-
infection that is normalized to the p24 inoculum.
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we mapped key resistance mutations identified in the chimeric
envelopes by site-directed mutagenesis to determine the effects
of these changes on resistance.
Results
Generation of vicriviroc-resistant RU570 HIV-1 variant in
PM-1 cells
PM-1 viral cultures were established as described in the
Materials and methods section and were assessed periodically for
susceptibility to vicriviroc in PBL replication assays between
weeks 12–93. Vicriviroc dose–response curves for viruses ob-
tained fromweeks 22 (Fig. 1A), 45 (Fig. 1B), 47 (Fig. 1C), and 93
(Fig. 1D) are depicted in Fig. 1. The RU570-VCV virus was
completely susceptible to vicriviroc until week 45 showing IC50
values b50 nM and maximum percent inhibition equivalent to
100% in dose–response curves similar to that depicted at week 22
(Fig. 2A). At weeks 45 and 47 incomplete dose–response curves
to vicriviroc were observed (Figs. 2B and C) with maximal
percent inhibition approximately 76% and 45%, respectively. As
expected, the RU570 passage control virus remained susceptible
to vicriviroc through 93 weeks of cell culture. By week 93,
complete resistance in the vicriviroc treated culture was dem-
onstrated by a flat dose–response curve to drug and a maximum
percent inhibition at approximately 30% (Fig. 2D).
In order to determine that viral replication in the presence of
vicriviroc was not due to co-receptor switching of this primary
isolate, we infected U87-CD4 cell lines that express CXCR4
with virus from the week 93 cultures. As has been reported for
other in vitro generated HIV-1 resistant variants to CCR5 co-
receptor antagonists (Kuhmann et al., 2004; Trkola et al., 2002;
Westby et al., 2007), the RU570 vicriviroc-resistant variant
(RU570-VCVres) from week 93 did not replicate in U87-CD4-
CXCR4 cells demonstrating that this resistant variant remained
CCR5-tropic only (data not shown).
Clonal sequence analysis of HIV-1 gp120
U87-CD4-CCR5 cells were infected with week 93 cultures
for RU570-PC and RU570-VCVres virus in the absence and
presence of vicriviroc, respectively. HIV-1 gp120 sequences
were amplified by PCR from genomic DNA isolated from
infected cells 48 h post-infection and clonal sequence analysis
of gp120 was performed. The amino acid changes in gp120
identified between the RU570-PC and RU570-VCVres included
10 dominant amino acid changes (present in ≥50% of resistant
clones) that were identified, throughout the RU570-VCVres
gp160 protein sequence, following analysis of 18 clones
compared with the amino acid sequence of the RU570-PC
virus (5 clones). The following dominant amino acid changes
were identified: E106K in C1, I165L in V2, A281T in C2,
K305R, R315Q, and K319T in the V-3 loop, T413N in V4,
P437S in C4, I467T in V5, and Q507R/E in C5 (see Fig. 2). In
addition, two amino acid changes in C3 (S363P and T373A),
two additional changes in the V3 loop (I317F and G321D), andone amino acid change in C5 (K503R) were found in b50% of
the clones.
Generation of chimeric envelopes by homologous
recombination in bacteria
Single-cycle assays using pseudotyped HIV-1 particles that
express a reporter gene in infected cells are used to address the
susceptibility of HIV-1 envelope clones to co-receptor antago-
nists. A luciferase reporter-gene located in the nef-coding re-
gion and a frame-shift mutation in the envelope gene in pNL4-
3-Env-Luc+ limit the detection of pseudovirus infectivity to a
single-round. These assays are also being used to diagnose co-
receptor usage for patients entering clinical trials for CCR5
antagonists (Coakley et al., 2005). Unfortunately, efforts to
generate pseudoviruses with gp160 clones obtained from
RU570-VCVres cultures using the standard pNL4-3Env
−Luc+
HIV-1 replication-incompetent vector resulted in pseudovirus
stocks with no detectable luciferase activity. In addition, a
majority of the gp160 clones from RU570 passage control (PC)
virus failed to generate viable pseudotyped HIV-1 particles.
Following screening of numerous gp160 clones, we eventually
identified a single functional gp160 clone that could be pseu-
dotyped with the HIV-1 vector (Fig. 3).
Therefore, we used an alternate strategy to generate func-
tional envelope clones from resistant viruses. Making use of
homologous recombination in bacteria, we cloned different
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background of the RU570-PC gp160 backbone in order to
determine if domain swapping would result in the transfer of the
resistance phenotype into this vicriviroc-susceptible passage
control envelope. Based on numerous studies using restriction-
site fragment swapping for mapping co-receptor determinants
within gp120 (Cho et al., 1998; Choe et al., 1996; Cocchi et al.,
1996), we reasoned that resistance might also tract with domain
swapping. Following homologous recombination of VCVres
gp120 into the RU570-PC gp160 construct, the chimeric en-
velope clones were sequenced to determine the co-ordinates of
recombination and were then used to generate HIV-1 pseudo-
typed particles. Fig. 2A depicts the 3 homologous recombinant
envelopes that were obtained in the background of RU570-PCFig. 4. (A) Schematic of the chimeric envelopes generated by homologous recombin
sequences from VCVres gp120 clones and the filled bars represent the envelope seque
changes that were identified in VCVres gp120 are designated by arrows using HXB2
assays were performed for each HIV-1 pseudovirus (□—ADA, ○—ADA-V3res, ■—
logistic curve-fit analysis with PrismGraphPad Software Version 4.0 (R2 values, ADgp160. Vicriviroc dose–response experiments in U87-CD4-
CCR5 cells were performed using HIV-1 particles pseudotyped
with the chimeric envelopes. As expected, the control RU570-
PC envelope was completely susceptible to vicriviroc with
an IC50 value of 0.1 nM and a 100% maximum inhibition.
Surprisingly none of the chimeric envelopes containing varying
lengths of C2-V5 VCVres gp120 were resistant to vicriviroc.
These chimeric pseudotyped HIV-1 particles displayed max-
imum inhibition levels of 100% at concentrations of vicriviroc
≥100 nM and the IC50 values calculated from dose–response
curves depicted in Fig. 2B ranged between 0.07 and 0.2 nM.
Since we routinely analyze the infectivity of pseudoviruses by
comparing the ratio of the luciferase activity (RLU) produced
per ng of p24 inoculum for each virus (relative infectivity), weation in BJ5183 E. coli bacterial cultures. The hatched bars represent the gp120
nce from ADA gp160 into which these sequences were recombined. Amino acid
amino acid coordinates. (B) Dose–response curves for vicriviroc-susceptibility
ADA-C2-V5res). Data were analyzed using a nonlinear regression 4-parameter
A: 0.94, ADA-V3res: 0.96, ADA-C2-V5res: 0.87).
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nificantly reduced relative infectivity (25-fold to 50-fold lower)
in comparison with HIV-1 particles pseudotyped with ADA
envelope (Fig. 3). Since the pseudotyped ADA envelope pro-
duced such robust activity, we tried homologous recombination
of VCVres gp120 with this completely heterologous, vicriviroc
susceptible envelope. Two recombinants containing different
fragment lengths of RU570-VCVres gp120 in ADA gp160
(ADA-V3res; HXB2 coordinates: aa 270–332; ADA-C2-V5res;
HXB2 coordinates: aa 270–468) were generated (Fig. 4A) and
characterized for infectivity and susceptibility to vicriviroc in
single-cycle HIV-1 pseudovirus assays.
Characterization of HIV-1 pseudoviruses containing ADA
chimeric envelopes
The luciferase activity for pseudoviruses generated with the
ADA chimeric envelopes was enhanced significantly relative to
the RU570-PC chimera although it was about 2- to 3-fold lower
than wt ADA envelope (Fig. 3). We next performed vicriviroc
susceptibility assays using the pseudoviruses generated with the
ADA chimeric envelopes. Assays were conducted in U87-CD4-
CCR5 cells using serial 10-fold dilutions of vicriviroc spanning
a 7–8 log10 molar range in inhibitor concentration and vicriviroc
susceptibility curves for these pseudoviruses are shown in
Fig. 4B. As expected, control HIV-1 particles pseudotyped
with ADA gp160 were completely susceptible to vicriviroc
with an IC50 value of 0.04 nM and a maximum response of
100% inhibition. Interestingly, pseudoviruses generated with the
ADA-V3res chimeric envelope containing only the V-3 loop
region from RU570-VCVres gp120 were completely susceptible
to vicriviroc despite containing 3 dominant mutations in V-3;
whereas pseudoviruses containing the ADA-C2-V5res chimericFig. 5. Variability in the percent maximal inhibition (MI) in single-cycle HIV-1 pseud
HIV-1 pseudovirus input based on p24 inoculum for ADA-C2-V5res pseudoviruses.
analysis with PrismGraphPad Software Version 4.0 (■—70 ng,□—35 ng,▵—2 ng,
the RU570-PC-C2-V5res pseudoviruses was observed (■—90 ng, □—45 ng, ▵—1envelope exhibited a resistant phenotype showing a reduction in
the maximum inhibition (MI) in vicriviroc dose–response
curves. This resistant phenotype has been previously reported
for other in vitro generated resistant variants (Pugach et al.,
2007;Westby et al., 2007). These data suggest that the additional
C3-V4-C4-V5 domains of gp120 are necessary for maintaining
vicriviroc resistance in the background of ADA gp160. Since the
V3-loop region from RU570-VCVres gp120 within a hetero-
logous background did not recapitulate resistance, these V3-
loop changes are most likely context dependent.
Effect of viral inoculum on maximum inhibition values
Since the ADA-C2-V5res chimeric envelope displayed a
vicriviroc-resistance phenotype and the activity was 25-fold
higher compared to the RU570-PC-C2-V5res chimeric, we
tested increasing doses of virus inoculum with the RU570
chimeric to see if this enabled the detection of resistance for this
envelope. Because of the limited infectivity of this chimeric
envelope (Fig. 5), we were only able to examine a 10-fold range
in p24 inocula. Even with very high amounts of inoculum
(90 ng p24), no change in the 100% maximum inhibition
occurred. Intriguingly, when the ADA-C2-V5res pseudovirus
infections were examined using increasing amounts of virus
inocula, the MI for vicriviroc decreased as the level of virus
increased (Fig. 5). At high virus inocula (70 ng p24), the plateau
level was approximately 55%, however the plateau level in-
creased with decreasing concentrations of virus to approxi-
mately 80% MI (2 ng p24). This effect was not seen for HIV-1
pseudoviruses generated with the parental ADA gp160 or
RU570-PC gp160 constructs. Using a similar range in virus
inocula, the MI values for these viruses remained at 100%
regardless of the virus concentration (data not shown).ovirus assays indicative of resistance to vicriviroc correlates with the amount of
Data were analyzed using a nonlinear regression 4-parameter logistic curve-fit
and R2 values 0.8, 0.9, 0.95, and 0.8 respectively), whereas no change in MI with
1 ng and R2 values 0.99, 0.97, 0.96, and 0.86, respectively).
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with vicriviroc resistance
To determine if resistance to vicriviroc is dependent upon
amino acid changes within individual domains of gp120 or on
the collective effect of changes throughout gp120, site-directed
mutagenesis of six dominant and two nondominant amino acid
changes present in the ADA-C2-V5res chimeric envelope gene
was performed. Single reverse amino acid changes were made
in ADA-C2-V5res at these eight positions by substituting these
amino acids with the corresponding amino acid present in the
passage control gp120 sequence. These mutations were ana-
lyzed for vicriviroc susceptibility in a single-cycle HIV-1
pseudovirus assay as described previously. Because of the dose-
dependent effect of viral inocula on MI, our mapping studies
were performed with at least four dilutions of pseudovirus
spanning the same range in p24 inoculum as ADA-C2-V5res
pseudovirus. The results were normalized to virus input (RLU/
ng p24) and therefore each data point represents the average of
triplicate measurements for each dilution (n=12). Data for
individual reverse amino acid substitution have been grouped
according to their domain location within gp120: V3 loop
(Fig. 6A), C3 (Fig. 6B), and V4-C4-V5 (Fig. 6C).
Of the three dominant amino acid changes found in the
RU570-VCVres gp120 V3 loop, the reverse mutation having the
most dramatic effect on resistance was the R305K substitution in
the N-terminal stem-region of the V3 loop. This amino acid
substitution resulted in an increase in the maximum inhibition by
vicriviroc from 70% to approximately 90% (Fig. 6A; Table 1).
These results are similar to those of Westby et al. (2007)
demonstrating increases in the MI for maraviroc-resistant
viruses following reverse substitution of single, and multiple
amino acids in the V3 loop that were acquired during in vitro
generated resistance. In contrast, the Q315R substitution in the
V3 loop had no effect on vicriviroc resistance as demonstrated
by the overlapping dose–response curves with ADA-C2-V5res
displayed in Fig. 6A. Likewise, combining the two V3-loop
reverse substitutions did not produce a cumulative effect and the
MI was similar to the single R305K substitution. When the
amino acid at position 319 in the crown region of the V3 loop
was changed (T319K), no functional pseudoviruses were
detected. In order to determine if the amino acid at position
319was V3-loop context dependent, this amino acid substitution
was combined with the R305K and Q315R amino acid
substitutions. Again, no functional HIV-1 pseudoviruses wereFig. 6. Dose–response curves for vicriviroc susceptibility assays performed with
HIV-1 pseudoviruses generated with chimeric envelope ADA-C2-V5res that
contain reverse amino-acid substitutions in gp120 for amino-acid changes
identified in PM-1 vicriviroc-resistant RU570 virus cultures compared to
RU570-PC. Data were analyzed using a nonlinear regression 4-parameter
logistic curve-fit analysis with PrismGraphPad Software Version 4.0. (A) V3-
loop mutations; ○—ADA env, ■—ADA-C2-V5res, □—R305K, ▴—Q315R,
×—R305K/Q315R, and R2 values 0.91, 0.87, 0.91, 0.92, and 0.90, respectively.
(B) C3 mutations;○—ADA env,■—ADA-C2-V5res,●—P363S,▴—A373T,
and R2 values 0.99, 0.87, 0.91, 0.92, and 0.90, respectively. (C) V4-C4-V5
mutations; ○—ADA env, ■—ADA-C2-V5res, ●—N413T, ▴—S437P, ×—
T467I, and R2 values 0.99, 0.92, 0.87, 0.96, 0.83, and 0.96, respectively.observed. Therefore, the effect of this amino acid on resistance
could not be determined in a single-cycle assay.
Single amino acid substitutions made in C3, V4, and V5 had
a lesser effect on the maximal percent inhibition. For each single
amino acid substitution made, the average plateau level was
lower than 80% inhibition and the change in the MI compared
to ADA-C2-V5res was ≤10% (Table 1). The S437P amino acid
Table 1
Effects of reverse amino acid changes in RU570 vicriviroc-resistant gp120 on
susceptibility to vicriviroc in a single-cycle HIV-1 pseudovirus assay
gp120 aa # a gp120 domain Maximum inhibition
(MI) b (%)
ΔMI c (%)
R305K V3 89.5±4.9 d +19.0±4.0
Q315R V3 70.7±7.0 +0.2±2.3
T319Ke V3 NA
R305K/Q315R V3 89.3 d +18.8
R305K/P363S V3/C3 86.9 d +16.4
R305K/A373T V3/C3 86.4±4.3 d +16.1±4.1
R305K/A373T/
T467I
V3/C3/V5 89.9 d +19.4
P363S C3 74.3 +3.8
A373T C3 73.2 +2.7
N413T V4 70.0 −0.5
S437P C4 65.1 −4.9
T4671 V5 75.6 +5.1
ADA-C2-V5res 70.5±7.0
RU570-PC 100.0
a Amino acid # represents HXB2 gp120 sequence.
b Values for ADA-C2-V5res represent the average±standard deviation for n=5
independent experiments; R305K, Q315R, R305K/A373T represent n=3 and all
other values represent the average of at least two independent experiments.
Each experiment represents dose–response data for at least four dilutions of
pseudovirus.
c ΔMI represents the change in the average maximum percent inhibition for
each mutation compared to the average maximum percent inhibition for ADA-
C2-V5res gp160; (+) ΔMI value correlates to an increased susceptibility to
vicriviroc.
d Pb0.05 compared to ADA-C2-V5res.
e Loss of infectivity in a single-cycle assay; NA, not applicable.
Fig. 7. Dose–response curves for vicriviroc susceptibility assays performed with
HIV-1 pseudoviruses generated with chimeric envelope ADA-C2-V5res con-
taining multiple reverse amino-acid substitutions in gp120. Data were analyzed
using a nonlinear regression 4-parameter logistic curve-fit analysis with
PrismGraphPad Software Version 4.0 (○—ADA env, ■—ADA-C2-V5res,
●—R305K, ▴—R305K/A373T, ×—R305K/A373T/T467I, and R2 values
0.91, 0.87, 0.91, 0.88, and 0.89, respectively).
Fig. 8. Vicriviroc dose–response curves for replicatingHIV-1 NL4-3-AD8 (-□-),
and HIV-NL4-3-AD8 containing the C2-V5res (-■-) and V3res (-●-) gp120
domains from RU570-VCVres gp120 in U87-CD4-CCR5 cells.
394 R.A. Ogert et al. / Virology 373 (2008) 387–399substitution in the C4 domain of gp120 had no effect on the MI.
When amino acid substitutions from C3 only or C3 and V5 were
combined with the dominant R305K V3-loop substitution, the
average MI observed did not increase beyond 90% and was
similar to the single R305K substitution as shown by the nearly
overlapping dose–response curves in Fig. 7.
Vicriviroc susceptibility assays with replication competent
chimeric HIV-1 viruses
CCR5 inhibitor resistance was previously reported to be
influenced by the assay format in which resistance is evaluated
(Pugach et al., 2007). In assays performed in PBMCs, it was
noted that differences were found in the phenotype of a resistant
virus displaying noncompetitive resistance in a single-cycle
format (plateau effect) versus replication enhancement in a
multi-cycle assay. In order to evaluate differences in suscept-
ibility profiles between single-cycle and multi-cycle infection
assays in U87-CD4-CCR5 cells, we generated replication
competent viruses expressing the chimeric gp120 envelopes.
Restriction fragments corresponding to HXB2 aa 203–608
within ADA-V3res and ADA-C2-V5res chimeric envelopes were
transferred to an NL4-3-AD8 HIV-1 molecular clone by unique
restriction-site digestion and religation. Infectious virus gener-
ated in 293T cells was used to infect U87-CD4-CCR5 cells in
the presence of increasing concentrations of vicriviroc. Dose–response data for these viruses are represented in Fig. 8. The
replication competent HIV-1 virus containing the ADA-C2-
V5res chimeric envelope sequence was resistant to vicriviroc as
demonstrated by the incomplete dose–response curve to
vicriviroc displaying a MI at approximately 50% in U87-
CD4-CCR5 cells. This resistant virus appears to exhibit the
same resistance phenotype (plateau effect) in both assay for-
mats. Since the previously published results were performed in
PBMCs which would contain secreted chemokines, our results
are not directly comparable to those of Pugach et al. because of
the differences in experimental conditions. Both NL4-3-AD8
and the NL4-3-AD8-V3res virus containing just the V3-loop
region from the resistant gp120 clone were completely suscep-
tible to vicriviroc (IC50=0.025 nM).
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Single-cycle pseudovirus assays are routinely used to char-
acterize envelope genes from viruses resistant to entry inhibitors.
This assay format enables measurement of the efficiency of viral
entry for multiple envelopes in a common HIV-1 backbone.
In addition, pseudovirus assays have been adapted for high-
throughput analysis of clinical samples (Whitcomb et al., 2007).
However, the activity level of pseudovirus particles can vary
widely for envelope genes cloned from cell-culture generated
resistant strains (Westby et al., 2007) or clinical samples. In the
present study, we found that pseudoviruses generated with
cloned gp160 genes from RU570-VCVres did not produce a
measurable signal after infection, and therefore could not be
used for characterization of the RU570-VCVres envelope. To
overcome this problem, we tried chimeric gp160 envelopes
generated with both homologous and heterologous backbones
in an effort to increase pseudovirus infectivity. Heterologous
chimeric envelopes, generated between the ADA and RU570-
VCVres envelope genes, were found to produce robust signals in
the pseudovirus assay and were utilized for further characteriza-
tion of the genotypic and phenotypic determinants of resistance
for RU570-VCVres.
Our results demonstrate that resistance to a co-receptor
antagonist for an HIV-1 primary isolate can be predominantly
contained within a 200-amino acid gp120 domain when trans-
ferred into a heterologous, susceptible envelope clone. While
domain swapping with gp120 was done for resistance mapping
studies with the AD101-resistant CC1/85 chimeric molecular
clones, it was into the background of the parental isolate
(Kuhmann et al., 2004). In that regard, the gp120 domain (aa
271–386) that showed resistance following restriction-site
digestion and re-ligation overlaps with the same region that
we identified but ends at the beginning of V4. Therefore, it was
surprising that our chimeric envelopes generated in the back-
ground of the RU570-PC envelope did not display a resistance
phenotype in a single-cycle assay. Based on the lower infec-
tivity observed in pseudovirus assays with these chimeras, it is
possible that these envelopes have an overall lower receptor
binding affinity. Detection of resistance likely requires a
threshold level of envelope affinity that is not achieved with
the resistant envelopes in the single round pseudovirus infection
assay. Alternatively, it is possible that the rearrangement of
gp120 upon binding CD4 and subsequently CCR5 leading to
disassembly of gp120/gp41 and triggering of the fusion peptide
in the N-terminus of gp41 may be more efficient in the ADA
chimera.
Using the heterologous chimeric envelope from ADA-C2-
V5res, we used site-directed mutagenesis to revert amino acid
changes identified within this C2-V5 domain back to the amino
acids found in the passage control virus. We found that a single
amino acid substitution at position 305 in the V3 loop had the
most significant impact on resistance. In our studies, restoration
of the 305K residue identified in the passage control sequence
into the V3 loop of the resistant envelope conferred partial
susceptibility to vicriviroc. Interestingly, this same amino acid
change also occurred in the V3 loop of the AD101-resistantvirus CC1/85 (Kuhmann et al., 2004) and has also been
identified in several patients who experienced viral break-
through in a phase II clinical study that combined vicriviroc
with an optimized background antiviral regimen (Strizki et al.,
2006). Recently, Westby et al. described a maraviroc-resistant
virus RU570 that contained a deletion of amino acids 315–317
in the V3 crown that conferred resistance to MVC. This pattern
of amino acid changes is quite different from the RU570-
VCVres V3-loop changes we observed; however, an identical
amino acid change occurred at position 319 in both resistant
variants. In our studies, when this T319K reverse amino acid
change was made in the V3 crown, a complete loss of infectivity
occurred in both HIV-1 pseudoviruses and replicating virus.
Several reports have identified that position 319 in the V3
crown can contribute to both variations in sensitivity to entry
inhibitors and replication fitness (Lobritz et al., 2007; Mosier
et al., 1999; Safarian et al., 2006; Torre et al., 2000). In addition
to the V3-loop changes, when single amino acid changes were
made to individual residues outside the V3 loop, less significant
changes in the MI plateau height were observed. Also, several
combinations of amino acids outside the V3 loop in conjunction
with the dominant R305K substitution did not increase the MI
further than the single R305K substitution. These data suggest
that a collective contribution of a majority of the amino acids
outside the V3 loop in conjunction with the R305K substitution
may be needed to restore complete susceptibility to vicriviroc.
However, we cannot rule out whether position 319 has an effect
on resistance.
The region of gp120 from RU570-VCVres, encompassed in
ADA-C2-V5res, is well known for its interactions with the
CCR5 co-receptor. Results from numerous studies have dem-
onstrated that the V3 crown interacts with CCR5 primarily
through the second extracellular loop, and that the V3 base
region together with C4 residues in the bridging sheet forms a
binding pocket that engages sulfated-tyrosine residues in the N-
terminus of CCR5 (Cormier and Dragic, 2002; Hartley et al.,
2005; Huang et al., 2007, 2005; Liu et al., 2003; Napier et al.,
2007; Rizzuto et al., 1998). Our results suggest that both the V3-
loop and C4 regions from RU570-VCVres were necessary to
confer vicriviroc resistance in ADA-C2-V5res. The ADA-V3res
chimera, containing only the V3-loop from RU570-VCVres, was
readily able to use the CCR5 receptor in the absence of
vicriviroc, but was not able to enter via the drug-bound form.
Thus RU570-VCVres may require the unique structural features
of both the V3-loop and C4 domain of the resistant viral
envelope to interact with the vicriviroc-bound receptor. The
importance of the C4 region from RU570-VCVres suggests that
the interaction with the N-terminus of CCR5 could be especially
important for the development of vicriviroc resistance. Inter-
estingly, a V3 crown deleted HIV-1 R3A strain, TA1, which
developed dependence on the N-terminus of CCR5 for viral
entry during serial passage in culture, was found to be resistant
to CCR5 entry antagonists (Laakso et al., 2007). It is possible
that RU570-VCVres may also be more dependent on the N-
terminus of CCR5 for viral entry in the presence of vicriviroc.
Future studies utilizing specific CCR5 mutant receptors will be
required to validate this hypothesis.
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ated with the ADA-C2-V5res chimeric envelope gene in single-
cycle assays did not result in shifts in vicriviroc IC50 values.
Rather, the observed phenotype manifested as a reduction in the
MI, previously suggested to be the result of an increased affinity
for the drug-bound form of CCR5 (Pugach et al., 2007; Westby
et al., 2007). As was proposed in these studies, when the affinity
of the virus for inhibitor-bound CCR5 increases, the MI in drug
susceptibility assays is reduced. Therefore, changes in the
plateau height were proposed to be phenotypic markers of
CCR5 co-receptor inhibitor resistance (Westby et al., 2007).
However, in previous studies (Pugach et al., 2007; Westby et al.,
2007), no mention of variations in plateau levels based on viral
input was reported. This could be of significance since we found
that plateaus in MI in single-cycle pseudovirus assays for the
ADA-C2-V5res chimeric envelopes directly correlated with
virus input. In addition, the plateau levels in MI displayed by the
parental RU570 vicriviroc-resistant virus are also dependent on
virus dose in single-cycle susceptibility assays (P. Buontempo
and R. Ralston, unpublished observations). Therefore, this phe-
nomenon is not unique to the ADA-C2-V5res chimeric en-
velope, or the pseudovirus assay. This is the first report of an
entry inhibitor resistant virus that displays a dose dependant
degree of resistance. Further analysis using carefully controlled
assays and additional resistant envelopes are needed to deter-
mine if other resistant viruses display this phenomenon. In
addition, more accurate assays that measure envelope affinity to
drug-bound receptor may help to clarify the mechanism of dose-
dependent resistance.
In summary, this approach utilizing chimeric envelope genes
offers an alternative method to define resistance to co-receptor
antagonists beyond cloning the full-length envelope which does
not always result in functional pseudoviruses. This technique
demonstrated that transferring a C2-V5 gp120 domain into a
heterologous envelope by homologous recombination recapi-
tulates resistance to a co-receptor antagonist in the chimeric
envelope, therefore limiting the need for unique restriction sites
or transferring envelope into shuttle vectors. This methodology
may prove to be useful for monitoring the development of
resistance to co-receptor antagonists in HIV-1 infected patients.
Materials and methods
Reagents
Vicriviroc was synthesized at Schering-Plough Research
Institute, Kenilworth, NJ. The pSI expression vector was pur-
chased from Promega Corp. (Madison, WI).
HIV-1 plasmids and HIV-1 primary isolates
The HIV-1 clade G RU570 primary isolate and the pNL4-3-
AD8 molecular clone were obtained from the NIH AIDS
Research and Reference Reagent program. The pNL4-3E-Luc+
and pSV7d-ADA gp160 plasmids were obtained from John
Moore, Weill Medical College of Cornell University, New
York, NY. The pcDNA3.1-RU570 gp160 clone (Parental) wasconstructed as follows. PBL cultures were infected with the
RU570 primary isolate and an HIV DNA fragment correspond-
ing to HXB2 nucleotide sequence 5739→8920 was PCR
amplified from cell DNA using Platinum Pfx DNA polymerase
(InVitrogen Corp., Carlsbad, CA) with the following primers:
Vpr-(F)-5′-ATAAGAATTCTGCAACAACTGCTG-3′
(HXB2: 5739–5762)
Nef-(R)-5′-CTCCATGTTTTTCTAGGTCTCGAGA-3′
(HXB2: 8896–8920)
The PCR product was gel purified and cloned into pCR®-
Blunt II Topo vector (Invitrogen Corp.). RU570 gp160 was
amplified from this construct using the following envelope
specific primers:
Forward: 5′-CACCATGAGAGTGAAGGGGATACAGA-
AG-3′
Reverse: 5′-CCTCCCATTTTATAGCAAAGCTCTTTC-3′
The 2.5 kb envelope PCR product was gel purified and
cloned directly into pcDNA3.1, Version C vector (Invitrogen
Corp).
Cell lines
The neoplastic T-cell line, PM-1, was obtained from the NIH
AIDS Research and Reference Reagent program. PM-1 cells
were maintained in RPMI medium supplemented with 10%
fetal bovine serum (FBS). U87 astroglioma cells expressing
CD4 only, or with CCR1, CCR2, CCR3, CCR5, or CXCR4
were obtained from Dr. Dan Littman, New York University.
Cells expressing CD4 only were maintained in DMEM
supplemented with 10% FBS and 500 μg/ml G418 and cells
expressing both CD4 and chemokine receptors were maintained
in the same medium plus 1 μg/ml puromycin. 293T cells (CRL-
11268) were purchased from ATCC (Manassas, VA) and main-
tained in DMEM supplemented with 10% FBS and 300 μg/ml
G418. PBL preparations from normal blood donors were
obtained by leukophoresis performed at the New York Blood
Center. PBLs from each donor were purified by centrifugation
over a Ficoll-Hypaque density gradient (2000 rpm, 30 min). The
cells were washed twice with PBS and pools from 6 to 8 donors
were frozen in aliquots (5×107 cells per vial). Cells were
cultured in RPMI supplemented with 10% FBS and 50 U/ml
interleukin-2 (IL-2) and stimulated with 5 μg/ml phytohemag-
glutinin for 3 days prior to infection.
In vitro generation of RU570 virus cultures resistant to
vicriviroc
The Hut 78 derived PM-1 (Lusso et al., 1995) T-cell line was
infected with a parental PBL stock of HIV-1 RU570 for 1 week
prior to the initiation of vicriviroc selection starting at 0.1 nM.
PM-1 cell cultures were passaged weekly by transferring 1 ml of
cell culture supernatant and one tenth of the infected cells into
fresh PM-1 cultures (1–2×106) in the absence (passage control
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Culture supernatants were subsequently used to re-infect fresh
PM-1 cells weekly. Viral supernatants and infected cells were
collected periodically for p24 antigen titers, vicriviroc sensitivity
testing in PBL described below in the viral replication assay
section, and sequence analysis. RU570 virus initially grew
poorly in the presence of vicriviroc, hence the concentration of
vicriviroc was held below 1 nM for the first 12 weeks. As the
replication of RU570 in the presence of vicriviroc increased, the
concentration of vicriviroc was slowly increased to 400 nM
between weeks 12 and 22 and this concentration was held
constant until week 36. To select for minor populations of highly
resistant variants that may have emerged, the concentration of
vicriviroc was escalated to 10 μM at week 36 and cultures were
maintained in 10 μM vicriviroc until viral replication remained
consistent. By approximately week 56, VCV-treated cultures
were replicating to similar levels compared to the passage
control cultures and maintained consistently robust growth up to
93 weeks when cultures were terminated.
Viral replication assays
IL-2/PHA-stimulated PBL were seeded into 96-well plates
(200,000 cells/well) pretreated with an equal volume of medium
plus vicriviroc or medium only at 37 °C for 1 h. The plates were
centrifuged at 300×g for 10 min and the media aspirated and
replaced with 20 μl of fresh medium with or without compound.
The cells were then infected in triplicate using 20 μl of viral
supernatant (RU570) from 3hr to overnight at 37 °C. The cells
were washed twice with PBS to remove residual viral inoc-
ulums and cultured in the presence or absence of vicriviroc for
4 to 6 days. Viral replication was assessed by measuring p24
antigen production by ELISA. The IC50 and IC90 values for
vicriviroc susceptibility with these viruses were determined by
analyzing dose–response curves using a 4-parameter logistic
curve fit model with Prism GraphPad Software Version 4.0
(San Diego, CA).
Genotypic analysis of HIV-1 gp120 sequences
U87-CD4-CCR5 cells were infected with RU570 passage
control or RU570 vicriviroc-resistant viruses collected follow-
ing 93 weeks in culture. Forty-eight hours post infection total
cellular DNA was isolated using Qiagen DNeasy tissue kit
(Valencia, CA) and HIV-1 gp120 sequences were amplified by
DNA-PCR from genomic DNA using the following restriction-
site designed primers: SfiI-gp120 1F 5′-GCGGCCCAGCC-
GGCCAVAGTGAWGGRGAWACAGARGAATTGG-3′ cor-
responding to the HXB2 genome nucleotide sequence 6228–
6255 and XhoI-gp120 1R 5′-GGCTCGAGATCTTTTTTCTCT-
CYSCACCACTCTTCTCY-3′ corresponding to the HXB2
genome nucleotide sequence 7729–7757. Special nucleotide
designators are as follows:V=A/C/G,W=A/T, R=A/G,Y=C/T.
HIV-1 gp120 sequences were amplified with Roche Expand High
Fidelity PCR system (Roche Applied Science, Mannheim,
Germany) using the following 30 cycle elongation program:
94 °C, 30 s, 55 °C, 45 s, and 68 °C, 4 min. PCR products weredigested with SfiI and XhoI restriction endonucleases (New
England Biolabs, Beverly, MA), gel purified on 1% agarose and
cloned directly into pSECTag2 (Hygro A) vector (InVitrogen
Corp., Carlsbad, CA). DNA sequence analysis of individual
clones was performed using a CEQ 2000 Dye terminator cycle
sequencer (Beckman-Coulter Inc., Fullerton, CA).
Homologous recombination of HIV-1 gp120 fragments into
pSV7d-ADAgp160 and pSI-RU570 PC gp160 expression
vectors
The pSI-RU570 PC gp160 expression vector was constructed
following PCR amplification of gp160 using restriction-site
designed primers: MluI-Env4F 5′-GGGACGCGTATGAVAGT-
GAWGGRGAW-3′ and XbaI-Env4R 5′-AAATCTAGATTT-
GACMAYTTGCCHCCCATYTTA-3′ corresponding to
envelope sequences flanking the start and stop codons of HIV-1
gp160, respectively. Special nucleotide designators are M=A/C
and H=A/C/T. HIV-1 gp160 sequences were amplified with
Roche Expand High Fidelity PCR system (Roche Applied
Science, Mannheim, Germany) using the following 30 cycle
elongation program: 94 °C, 30 s, 55 °C, 45 s, and 68 °C, 7 min.
PCR products were digested with MluI and XbaI restriction
endonucleases (NewEnglandBiolabs, Beverly,MA), gel purified
on 1% agarose, and cloned directly into the pSI expression vector.
Homologous recombination of RU570 vicriviroc-resistant
gp120 (RU570-VCVres) into the pSI-RU570 passage control
gp160 (RU570-PC) expression vector was performed as follows.
The RU570-VCVres gp120 clone #8 in pSECTag2 was digested
with AleI andMfeI restriction endonucleases and the 730-bp C2-
C5 gp120 fragment (HXB2 gp120 nucleotides 681–1432; gp120
aa position 228–478) was gel-purified on 1.0% agarose. The pSI-
RU570-PC expression vector was digested with BsrGI and SbfI
restriction endonucleases, followed by alkaline phosphatase
treatment. The 5.8 kb vector fragment was gel purified on 1%
agarose. Homologous recombination was performed using a 10-
fold molar excess of gp120 fragment to vector for transformation
of chemically competent BJ5183 E. coli, and individual colonies
were screened by PCR for successful recombination.
Homologous recombination of the V2-C5 gp120 fragment
from RU570-PC gp120 clone #16 and RU570-VCVres gp120
clone #8 was performed following restriction endonuclease
digestion of constructs with MfeI and gel purification of the
838 bp V2-C5 gp120 fragments (HXB2 gp120 nucleotides
533–1431; gp120 aa position 185–478). The pSV7d-ADA
gp160 expression vector was digested with BglII and BstZ17I
restriction endonucleases, alkaline phosphatase treated, and the
5.1 kb vector was gel purified on 1% agarose. A 50:1 ratio of
V2-C5res gp120 fragment to vector was used to transform
chemically competent BJ5183 E. coli, and individual colonies
were screened by PCR for successful recombination.
Generation and characterization of HIV-1 pseudoviruses
HIV-1 pseudoviruses were produced in 293Tcells by calcium
phosphate transfection of pNL4-3E-Luc+ and HIV-1 envelope
expression vectors using ProFection® Mammalian Transfection
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harvested in culture supernatants 48 h post-transfection and
supernatants were clarified of cell debris by centrifugation at
1500×g for 10 min. Single-cycle infection assays were generally
performed on the same day HIV-1 pseudovirus was harvested. To
assess susceptibility to CCR5 co-receptor antagonists, 5000 U87-
CD4-CCR5 cells/well were seeded into 96-well luminometer
plates (Perkin Elmer) and plates were incubated overnight at
37 °C. The next day, serial 10-fold dilutions of inhibitor in cell
culture medium (10 μM→1.0 pM) were added to wells 1 h prior
to the addition of HIV-1 pseudovirus plus inhibitor. Plates were
incubated for 72 h, and luciferase activity was analyzed by adding
50 μl of BrightGlo™ luciferase assay buffer and plates were read
on a Dynex luminometer (300 mSec/well). Relative light units
(RLU) were normalized to virus dose, measured as ng p24, and
percent inhibition was calculated as follows: 100− [average
normalized RLU for HIV-1 pseudovirus plus drug/average nor-
malized RLU for HIV-1 pseudovirus from control wells without
drug]×100. Dose–response data were analyzed using a nonlinear
regression 4-parameter logistic curve fit program with Prism
GraphPad Software Version 4.0 (San Diego, CA).
Site-directed mutagenesis (SDM) of gp120 amino acids
SDM of individual, gp120 amino acids in the pADA-C2-
V5res clone was performed using QuikChange SDM kit
(Stratagene, La Jolla, CA). Amino acid changes corresponding
to HXB2 gp120 amino acid coordinates are as follows: R305K,
Q315R, T319K, P363S, A373T, N413T, S437P, and T467I. All
sequence changes were verified by DNA sequence analysis.
HIV-1 molecular clones
The pNL4-3-AD8 molecular clone was modified by deleting
650 bp of cDNA sequence flanking the 5′LTR, thereby creating a
unique StuI site within gp120. The ADA-V3res and ADA-C2-
V5res chimeric envelopes were digested with StuI and AleI re-
striction endonucleases and the 1.2 kb env fragments corre-
sponding to aa 203–608 (HXB2 gp160 aa coordinates) were gel
purified on 1%agarose. These fragmentswere cloned directly into
pNL4-3-AD8 digested with the same restriction endonucleases
and all constructs were verified by DNA sequence analysis.
Generation of replication-competent HIV-1 viruses
293T cells were transfected with pNL4-3-AD8, pNL4-3-
AD8-C2-V5res, and pNL4-3-AD8-V3res molecular clones using
Superfect transfection reagent (Qiagen Corp., Vencia, CA) and
HIV-1 virus was harvested in supernatants 48 hr post
transfection.
Nucleotide sequence accession numbers
The followingHIV-1 envelope sequences have been submitted
to GenBank: 2 sequences for RU570 gp160 (accession no.
EU090200–EU090201) and 22 gp120 sequences for RU570-
derived viruses (accession no. EU090202–EU090223).References
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